Why Amarin Shares Are Plunging Wednesday

Amarin Corporation plc AMRN shares were plummeting on above-average volume as an appeal hearing on the Vascepa fish oil capsule patent gets underway. 

What Happened: Amarin appealed against a late March ruling that its Vascepa patents were invalid. The invalidation of the patents would pave the way for potential generic launches by Dr.Reddy's Laboratories Ltd RDY and Hikma.

The three-judge appeals panel does not improve Amarin's chances of winning the Vascepa patent litigation appeal, SVB Leerink analyst Ami Fadia said in a Wednesday note.

Of the three judges, only one has a track record of voting against prima facie, while the other two have not voted against this procedure in the past, the analyst said. 

"We would not consider either judge to be in the upper half of the 12 possible active judges most likely to side with Amarin." 

Overall, the composition of the three-judge panel has not improved Amarin's chances of winning the appeal, Fadia said.

Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

Why It's Important: Vascepa is Amarin's synthetic fish oil pill that is used to reduce triglyceride levels. The company received a label expansion for Vascepa in December to include the indication of cardiovascular risk reduction.

Vascepa accounts for the bulk of Amarin's net product revenue and roughly two-thirds of its licensing and royalty revenues.

A patent loss would mean considerable erosion in Amarin's Vascepa revenue. 

"A reversal of the patent invalidation ruling, if it occurs, would likely secure exclusivity for branded Vascepa in the US for a significant period of time (until late in the decade, we think), and is an outcome which we believe is currently not priced-in to share," Aegis Capital's Nathan Weinstein said in a note. 

AMRN Price Action: Amarin's stock was down 28.57% at $5.19 at the time of publication Wednesday. 

Posted In: Aegis CapitalAmi FadiaNathan WeinsteinSVB LeerinkVascepaAnalyst ColorNewsHealth CareLegalAnalyst RatingsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.